PMC:1064895 / 2667-2921
Annnotations
test3
{"project":"test3","denotations":[{"id":"T2189","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T2188","span":{"begin":60,"end":89},"obj":"Protein"},{"id":"T2187","span":{"begin":46,"end":56},"obj":"Negative_regulation"},{"id":"T2155","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T2154","span":{"begin":60,"end":89},"obj":"Protein"}],"relations":[{"id":"R1090","pred":"themeOf","subj":"T2188","obj":"T2187"},{"id":"R1091","pred":"themeOf","subj":"T2189","obj":"T2187"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
BioNLP16_Messiy
{"project":"BioNLP16_Messiy","denotations":[{"id":"T3714","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T3713","span":{"begin":60,"end":89},"obj":"Protein"},{"id":"T3746","span":{"begin":46,"end":56},"obj":"Negative_regulation"}],"relations":[{"id":"R1776","pred":"themeOf","subj":"T3713","obj":"T3746"},{"id":"R1777","pred":"themeOf","subj":"T3714","obj":"T3746"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
BioNLP16_DUT
{"project":"BioNLP16_DUT","denotations":[{"id":"T4635","span":{"begin":46,"end":56},"obj":"Negative_regulation"},{"id":"T4603","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T4602","span":{"begin":60,"end":89},"obj":"Protein"}],"relations":[{"id":"R2458","pred":"themeOf","subj":"T4602","obj":"T4635"},{"id":"R2459","pred":"themeOf","subj":"T4603","obj":"T4635"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
2_test
{"project":"2_test","denotations":[{"id":"15642134-12810200-4202009","span":{"begin":251,"end":252},"obj":"12810200"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
biosemtest
{"project":"biosemtest","denotations":[{"id":"T2741","span":{"begin":226,"end":237},"obj":"UMLS/C0302350"},{"id":"T2738","span":{"begin":60,"end":81},"obj":"UP/P13296"},{"id":"T2717","span":{"begin":14,"end":22},"obj":"UMLS/C0205210"},{"id":"T2711","span":{"begin":60,"end":81},"obj":"UP/P59694"},{"id":"T2704","span":{"begin":60,"end":81},"obj":"UP/P19101"},{"id":"T2697","span":{"begin":222,"end":225},"obj":"UMLS/C0205314"},{"id":"T2692","span":{"begin":60,"end":81},"obj":"UP/O77764"},{"id":"T2691","span":{"begin":14,"end":22},"obj":"UMLS/C1555900"},{"id":"T2688","span":{"begin":60,"end":81},"obj":"UP/P51435"},{"id":"T2678","span":{"begin":60,"end":81},"obj":"UP/Q8MKG8"},{"id":"T2671","span":{"begin":60,"end":81},"obj":"UP/P59684"},{"id":"T2665","span":{"begin":238,"end":250},"obj":"UMLS/C0870325"},{"id":"T2664","span":{"begin":14,"end":22},"obj":"UMLS/C1611832"},{"id":"T2657","span":{"begin":60,"end":81},"obj":"UP/P36939"},{"id":"T2656","span":{"begin":60,"end":81},"obj":"UP/Q8JFG3"},{"id":"T2647","span":{"begin":60,"end":81},"obj":"UP/P33620"},{"id":"T2642","span":{"begin":60,"end":81},"obj":"UP/P79374"},{"id":"T2637","span":{"begin":60,"end":81},"obj":"UP/Q06599"},{"id":"T2636","span":{"begin":60,"end":81},"obj":"UP/P59695"},{"id":"T2635","span":{"begin":60,"end":81},"obj":"UP/P79337"},{"id":"T2633","span":{"begin":60,"end":81},"obj":"UP/P59693"},{"id":"T2632","span":{"begin":60,"end":81},"obj":"UP/O35734"},{"id":"T2624","span":{"begin":14,"end":22},"obj":"UMLS/C1608518"},{"id":"T2623","span":{"begin":60,"end":81},"obj":"UP/P29553"},{"id":"T2622","span":{"begin":60,"end":81},"obj":"UP/P23563"},{"id":"T2621","span":{"begin":60,"end":81},"obj":"UP/Q8HZD9"},{"id":"T2603","span":{"begin":144,"end":147},"obj":"UMLS/C1554080"},{"id":"T2584","span":{"begin":60,"end":81},"obj":"UP/P23383"},{"id":"T2575","span":{"begin":60,"end":81},"obj":"UP/Q1G1A2"},{"id":"T2568","span":{"begin":60,"end":81},"obj":"UP/Q8WNR1"},{"id":"T2561","span":{"begin":60,"end":81},"obj":"UMLS/C1456820"},{"id":"T2559","span":{"begin":60,"end":81},"obj":"UP/Q9BEA1"},{"id":"T2558","span":{"begin":238,"end":250},"obj":"UMLS/C2347934"},{"id":"T2556","span":{"begin":60,"end":81},"obj":"UP/Q19LH4"},{"id":"T2541","span":{"begin":222,"end":225},"obj":"UMLS/C1553390"},{"id":"T2475","span":{"begin":32,"end":40},"obj":"UMLS/C1706701"},{"id":"T2474","span":{"begin":60,"end":81},"obj":"UMLS/C2700093"},{"id":"T2472","span":{"begin":23,"end":31},"obj":"UMLS/C0814225"},{"id":"T2470","span":{"begin":238,"end":250},"obj":"UMLS/C0185125"},{"id":"T2465","span":{"begin":60,"end":81},"obj":"UP/Q2MH05"},{"id":"T2464","span":{"begin":46,"end":56},"obj":"UMLS/C1999216"},{"id":"T2463","span":{"begin":60,"end":81},"obj":"UMLS/C0041368"},{"id":"T2458","span":{"begin":60,"end":81},"obj":"UP/Q539C2"},{"id":"T2447","span":{"begin":226,"end":237},"obj":"UMLS/C1553525"},{"id":"T2438","span":{"begin":32,"end":40},"obj":"UMLS/C1301820"},{"id":"T2435","span":{"begin":207,"end":218},"obj":"UMLS/C1527148"},{"id":"T2428","span":{"begin":60,"end":81},"obj":"UP/P04924"},{"id":"T2427","span":{"begin":60,"end":81},"obj":"UP/P01375"},{"id":"T2420","span":{"begin":60,"end":81},"obj":"UP/P16599"},{"id":"T2412","span":{"begin":161,"end":170},"obj":"UMLS/C1524094"},{"id":"T2403","span":{"begin":222,"end":225},"obj":"UMLS/C1578513"},{"id":"T2395","span":{"begin":96,"end":107},"obj":"UMLS/C0021764"},{"id":"T2381","span":{"begin":144,"end":147},"obj":"UMLS/C1706198"},{"id":"T2372","span":{"begin":60,"end":81},"obj":"UP/P51743"},{"id":"T2345","span":{"begin":132,"end":140},"obj":"UMLS/C0332206"},{"id":"T2335","span":{"begin":60,"end":81},"obj":"UMLS/C1323304"},{"id":"T2333","span":{"begin":96,"end":107},"obj":"UMLS/C1527200"},{"id":"T2332","span":{"begin":60,"end":81},"obj":"UP/O77510"},{"id":"T2328","span":{"begin":60,"end":81},"obj":"UP/Q75N23"},{"id":"T2324","span":{"begin":46,"end":56},"obj":"UMLS/C0243077"},{"id":"T2295","span":{"begin":238,"end":250},"obj":"UMLS/C1947919"},{"id":"T2283","span":{"begin":226,"end":237},"obj":"UMLS/C0039796"},{"id":"T2282","span":{"begin":60,"end":81},"obj":"UMLS/C1522668"},{"id":"T2281","span":{"begin":115,"end":122},"obj":"UMLS/C1705535"},{"id":"T2533","span":{"begin":171,"end":174},"obj":"UMLS/C2348947"},{"id":"T2505","span":{"begin":60,"end":81},"obj":"UP/P06804"},{"id":"T2499","span":{"begin":238,"end":250},"obj":"UMLS/C1547755"},{"id":"T2493","span":{"begin":60,"end":81},"obj":"UP/Q1WM27"},{"id":"T2265","span":{"begin":238,"end":250},"obj":"UMLS/C1533134"},{"id":"T2260","span":{"begin":148,"end":160},"obj":"UMLS/C0333348"},{"id":"T2258","span":{"begin":60,"end":81},"obj":"UP/P51742"},{"id":"T2252","span":{"begin":226,"end":237},"obj":"UMLS/C1547427"},{"id":"T2242","span":{"begin":161,"end":170},"obj":"UMLS/C0079189"},{"id":"T2236","span":{"begin":60,"end":81},"obj":"UP/P48094"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
pmc-enju-pas
{"project":"pmc-enju-pas","denotations":[{"id":"T2979","span":{"begin":252,"end":253},"obj":"-RRB-"},{"id":"T2978","span":{"begin":251,"end":252},"obj":"CD"},{"id":"T2977","span":{"begin":250,"end":251},"obj":"-LRB-"},{"id":"T2976","span":{"begin":237,"end":249},"obj":"NN"},{"id":"T2975","span":{"begin":225,"end":236},"obj":"JJ"},{"id":"T2974","span":{"begin":221,"end":224},"obj":"JJ"},{"id":"T2973","span":{"begin":218,"end":220},"obj":"IN"},{"id":"T2972","span":{"begin":206,"end":217},"obj":"NN"},{"id":"T2971","span":{"begin":202,"end":205},"obj":"DT"},{"id":"T2970","span":{"begin":199,"end":201},"obj":"IN"},{"id":"T2969","span":{"begin":193,"end":198},"obj":"NN"},{"id":"T2968","span":{"begin":183,"end":192},"obj":"JJ"},{"id":"T2967","span":{"begin":179,"end":182},"obj":"DT"},{"id":"T2966","span":{"begin":174,"end":178},"obj":"VB"},{"id":"T2965","span":{"begin":170,"end":173},"obj":"VB"},{"id":"T2964","span":{"begin":160,"end":169},"obj":"NN"},{"id":"T2963","span":{"begin":147,"end":159},"obj":"JJ"},{"id":"T2962","span":{"begin":143,"end":146},"obj":"JJ"},{"id":"T2961","span":{"begin":140,"end":142},"obj":"IN"},{"id":"T2960","span":{"begin":131,"end":139},"obj":"NN"},{"id":"T2959","span":{"begin":127,"end":130},"obj":"DT"},{"id":"T2958","span":{"begin":122,"end":126},"obj":"IN"},{"id":"T2957","span":{"begin":114,"end":121},"obj":"VB"},{"id":"T2956","span":{"begin":111,"end":113},"obj":"CD"},{"id":"T2955","span":{"begin":110,"end":111},"obj":"-RRB-"},{"id":"T2954","span":{"begin":108,"end":110},"obj":"NN"},{"id":"T2953","span":{"begin":107,"end":108},"obj":"-LRB-"},{"id":"T2952","span":{"begin":95,"end":106},"obj":"NN"},{"id":"T2951","span":{"begin":91,"end":94},"obj":"CC"},{"id":"T2950","span":{"begin":89,"end":90},"obj":"-RRB-"},{"id":"T2949","span":{"begin":87,"end":89},"obj":"NN"},{"id":"T2948","span":{"begin":86,"end":87},"obj":"-RRB-"},{"id":"T2947","span":{"begin":83,"end":86},"obj":"NN"},{"id":"T2946","span":{"begin":82,"end":83},"obj":"-LRB-"},{"id":"T2945","span":{"begin":75,"end":81},"obj":"NN"},{"id":"T2944","span":{"begin":66,"end":74},"obj":"NN"},{"id":"T2943","span":{"begin":60,"end":65},"obj":"NN"},{"id":"T2942","span":{"begin":57,"end":59},"obj":"IN"},{"id":"T2941","span":{"begin":46,"end":56},"obj":"NN"},{"id":"T2940","span":{"begin":41,"end":45},"obj":"IN"},{"id":"T2939","span":{"begin":32,"end":40},"obj":"VB"},{"id":"T2938","span":{"begin":23,"end":31},"obj":"NN"},{"id":"T2937","span":{"begin":14,"end":22},"obj":"JJ"},{"id":"T2936","span":{"begin":4,"end":13},"obj":"JJ"},{"id":"T2935","span":{"begin":0,"end":3},"obj":"DT"}],"relations":[{"id":"R1195","pred":"arg1Of","subj":"T2938","obj":"T2935"},{"id":"R1196","pred":"arg1Of","subj":"T2938","obj":"T2936"},{"id":"R1197","pred":"arg1Of","subj":"T2938","obj":"T2937"},{"id":"R1198","pred":"arg2Of","subj":"T2938","obj":"T2939"},{"id":"R1199","pred":"arg1Of","subj":"T2938","obj":"T2950"},{"id":"R1200","pred":"arg1Of","subj":"T2938","obj":"T2951"},{"id":"R1201","pred":"arg1Of","subj":"T2939","obj":"T2940"},{"id":"R1202","pred":"arg2Of","subj":"T2941","obj":"T2940"},{"id":"R1203","pred":"arg1Of","subj":"T2941","obj":"T2942"},{"id":"R1204","pred":"arg1Of","subj":"T2945","obj":"T2943"},{"id":"R1205","pred":"arg1Of","subj":"T2945","obj":"T2944"},{"id":"R1206","pred":"arg1Of","subj":"T2945","obj":"T2946"},{"id":"R1207","pred":"arg2Of","subj":"T2947","obj":"T2946"},{"id":"R1208","pred":"arg3Of","subj":"T2948","obj":"T2946"},{"id":"R1209","pred":"arg2Of","subj":"T2949","obj":"T2942"},{"id":"R1210","pred":"arg1Of","subj":"T2949","obj":"T2945"},{"id":"R1211","pred":"arg1Of","subj":"T2951","obj":"T2957"},{"id":"R1212","pred":"arg2Of","subj":"T2952","obj":"T2951"},{"id":"R1213","pred":"arg1Of","subj":"T2952","obj":"T2953"},{"id":"R1214","pred":"arg1Of","subj":"T2952","obj":"T2956"},{"id":"R1215","pred":"arg2Of","subj":"T2954","obj":"T2953"},{"id":"R1216","pred":"arg3Of","subj":"T2955","obj":"T2953"},{"id":"R1217","pred":"arg1Of","subj":"T2960","obj":"T2959"},{"id":"R1218","pred":"arg1Of","subj":"T2960","obj":"T2961"},{"id":"R1219","pred":"arg1Of","subj":"T2960","obj":"T2965"},{"id":"R1220","pred":"arg1Of","subj":"T2960","obj":"T2966"},{"id":"R1221","pred":"arg2Of","subj":"T2964","obj":"T2961"},{"id":"R1222","pred":"arg1Of","subj":"T2964","obj":"T2962"},{"id":"R1223","pred":"arg1Of","subj":"T2964","obj":"T2963"},{"id":"R1224","pred":"arg2Of","subj":"T2966","obj":"T2957"},{"id":"R1225","pred":"arg1Of","subj":"T2966","obj":"T2958"},{"id":"R1226","pred":"arg2Of","subj":"T2966","obj":"T2965"},{"id":"R1227","pred":"arg1Of","subj":"T2966","obj":"T2970"},{"id":"R1228","pred":"arg1Of","subj":"T2966","obj":"T2977"},{"id":"R1229","pred":"arg2Of","subj":"T2969","obj":"T2966"},{"id":"R1230","pred":"arg1Of","subj":"T2969","obj":"T2967"},{"id":"R1231","pred":"arg1Of","subj":"T2969","obj":"T2968"},{"id":"R1232","pred":"arg2Of","subj":"T2972","obj":"T2970"},{"id":"R1233","pred":"arg1Of","subj":"T2972","obj":"T2971"},{"id":"R1234","pred":"arg1Of","subj":"T2972","obj":"T2973"},{"id":"R1235","pred":"arg2Of","subj":"T2976","obj":"T2973"},{"id":"R1236","pred":"arg1Of","subj":"T2976","obj":"T2974"},{"id":"R1237","pred":"arg1Of","subj":"T2976","obj":"T2975"},{"id":"R1238","pred":"arg2Of","subj":"T2978","obj":"T2977"},{"id":"R1239","pred":"arg3Of","subj":"T2979","obj":"T2977"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-coref
{"project":"bionlp-st-ge-2016-coref","denotations":[{"id":"T3464","span":{"begin":95,"end":113},"obj":"Antecedent"},{"id":"T3463","span":{"begin":60,"end":89},"obj":"Antecedent"},{"id":"T3462","span":{"begin":143,"end":169},"obj":"Anaphor"}],"relations":[{"id":"R1726","pred":"boundBy","subj":"T3462","obj":"T3463"},{"id":"R1728","pred":"boundBy","subj":"T3462","obj":"T3464"}],"namespaces":[{"prefix":"_base","uri":"https://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-test-proteins
{"project":"bionlp-st-ge-2016-test-proteins","denotations":[{"id":"T3483","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T3482","span":{"begin":60,"end":89},"obj":"Protein"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-uniprot
{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T3688","span":{"begin":83,"end":89},"obj":"http://www.uniprot.org/uniprot/P01375"},{"id":"T3686","span":{"begin":83,"end":86},"obj":"http://www.uniprot.org/uniprot/P01375"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
GO-BP
{"project":"GO-BP","denotations":[{"id":"T2770","span":{"begin":206,"end":217},"obj":"http://purl.obolibrary.org/obo/GO_0032502"},{"id":"T2769","span":{"begin":66,"end":74},"obj":"http://purl.obolibrary.org/obo/GO_0070265"},{"id":"T2768","span":{"begin":66,"end":74},"obj":"http://purl.obolibrary.org/obo/GO_0019835"},{"id":"T2767","span":{"begin":66,"end":74},"obj":"http://purl.obolibrary.org/obo/GO_0008219"},{"id":"T2766","span":{"begin":66,"end":74},"obj":"http://purl.obolibrary.org/obo/GO_0001906"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
GO-MF
{"project":"GO-MF","denotations":[{"id":"T3515","span":{"begin":108,"end":113},"obj":"http://purl.obolibrary.org/obo/GO_0005149"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
sentences
{"project":"sentences","denotations":[{"id":"T2750","span":{"begin":0,"end":254},"obj":"Sentence"},{"id":"T20","span":{"begin":0,"end":254},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
simple1
{"project":"simple1","denotations":[{"id":"T3654","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T3653","span":{"begin":60,"end":89},"obj":"Protein"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
DLUT931
{"project":"DLUT931","denotations":[{"id":"T3795","span":{"begin":46,"end":56},"obj":"Negative_regulation"},{"id":"T3763","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T3762","span":{"begin":60,"end":89},"obj":"Protein"}],"relations":[{"id":"R1780","pred":"themeOf","subj":"T3762","obj":"T3795"},{"id":"R1782","pred":"themeOf","subj":"T3763","obj":"T3795"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-test-ihmc
{"project":"bionlp-st-ge-2016-test-ihmc","denotations":[{"id":"T4581","span":{"begin":46,"end":89},"obj":"Entity"},{"id":"T4567","span":{"begin":60,"end":89},"obj":"Protein"},{"id":"T4558","span":{"begin":147,"end":169},"obj":"Protein"},{"id":"T4525","span":{"begin":95,"end":113},"obj":"Protein"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-spacy-parsed
{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T3942","span":{"begin":253,"end":254},"obj":"."},{"id":"T3941","span":{"begin":252,"end":253},"obj":"NN"},{"id":"T3940","span":{"begin":251,"end":252},"obj":"CD"},{"id":"T3939","span":{"begin":250,"end":251},"obj":"JJ"},{"id":"T3938","span":{"begin":237,"end":249},"obj":"NNS"},{"id":"T3937","span":{"begin":225,"end":236},"obj":"JJ"},{"id":"T3936","span":{"begin":221,"end":224},"obj":"JJ"},{"id":"T3935","span":{"begin":218,"end":220},"obj":"IN"},{"id":"T3934","span":{"begin":206,"end":217},"obj":"NN"},{"id":"T3933","span":{"begin":202,"end":205},"obj":"DT"},{"id":"T3932","span":{"begin":199,"end":201},"obj":"IN"},{"id":"T3931","span":{"begin":193,"end":198},"obj":"NN"},{"id":"T3930","span":{"begin":183,"end":192},"obj":"JJ"},{"id":"T3929","span":{"begin":179,"end":182},"obj":"DT"},{"id":"T3928","span":{"begin":174,"end":178},"obj":"VBN"},{"id":"T3927","span":{"begin":170,"end":173},"obj":"VBZ"},{"id":"T3926","span":{"begin":160,"end":169},"obj":"NNS"},{"id":"T3925","span":{"begin":147,"end":159},"obj":"JJ"},{"id":"T3924","span":{"begin":143,"end":146},"obj":"JJ"},{"id":"T3923","span":{"begin":140,"end":142},"obj":"IN"},{"id":"T3922","span":{"begin":131,"end":139},"obj":"NN"},{"id":"T3921","span":{"begin":127,"end":130},"obj":"DT"},{"id":"T3920","span":{"begin":122,"end":126},"obj":"IN"},{"id":"T3919","span":{"begin":114,"end":121},"obj":"VBP"},{"id":"T3918","span":{"begin":111,"end":113},"obj":"CD"},{"id":"T3917","span":{"begin":110,"end":111},"obj":"-RRB-"},{"id":"T3916","span":{"begin":108,"end":110},"obj":"NNP"},{"id":"T3915","span":{"begin":107,"end":108},"obj":"-LRB-"},{"id":"T3914","span":{"begin":95,"end":106},"obj":"NN"},{"id":"T3913","span":{"begin":91,"end":94},"obj":"CC"},{"id":"T3912","span":{"begin":89,"end":90},"obj":"-RRB-"},{"id":"T3911","span":{"begin":88,"end":89},"obj":"VBN"},{"id":"T3910","span":{"begin":87,"end":88},"obj":":"},{"id":"T3909","span":{"begin":86,"end":87},"obj":"-RRB-"},{"id":"T3908","span":{"begin":83,"end":86},"obj":"NNP"},{"id":"T3907","span":{"begin":82,"end":83},"obj":"-LRB-"},{"id":"T3906","span":{"begin":75,"end":81},"obj":"NN"},{"id":"T3905","span":{"begin":66,"end":74},"obj":"NN"},{"id":"T3904","span":{"begin":60,"end":65},"obj":"NN"},{"id":"T3903","span":{"begin":57,"end":59},"obj":"IN"},{"id":"T3902","span":{"begin":46,"end":56},"obj":"NNS"},{"id":"T3901","span":{"begin":41,"end":45},"obj":"IN"},{"id":"T3900","span":{"begin":32,"end":40},"obj":"VBN"},{"id":"T3899","span":{"begin":23,"end":31},"obj":"NNS"},{"id":"T3898","span":{"begin":14,"end":22},"obj":"JJ"},{"id":"T3897","span":{"begin":4,"end":13},"obj":"JJ"},{"id":"T3896","span":{"begin":0,"end":3},"obj":"DT"}],"relations":[{"id":"R1947","pred":"det","subj":"T3896","obj":"T3899"},{"id":"R1951","pred":"amod","subj":"T3897","obj":"T3899"},{"id":"R1955","pred":"amod","subj":"T3898","obj":"T3899"},{"id":"R1958","pred":"nsubj","subj":"T3899","obj":"T3911"},{"id":"R1962","pred":"acl","subj":"T3900","obj":"T3899"},{"id":"R1966","pred":"prep","subj":"T3901","obj":"T3900"},{"id":"R1969","pred":"pobj","subj":"T3902","obj":"T3901"},{"id":"R1973","pred":"prep","subj":"T3903","obj":"T3902"},{"id":"R1977","pred":"compound","subj":"T3904","obj":"T3905"},{"id":"R1983","pred":"compound","subj":"T3905","obj":"T3906"},{"id":"R1984","pred":"pobj","subj":"T3906","obj":"T3903"},{"id":"R1985","pred":"punct","subj":"T3907","obj":"T3908"},{"id":"R1988","pred":"appos","subj":"T3908","obj":"T3906"},{"id":"R1990","pred":"punct","subj":"T3909","obj":"T3900"},{"id":"R1993","pred":"punct","subj":"T3910","obj":"T3899"},{"id":"R1997","pred":"ROOT","subj":"T3911","obj":"T3911"},{"id":"R2000","pred":"punct","subj":"T3912","obj":"T3911"},{"id":"R2004","pred":"cc","subj":"T3913","obj":"T3911"},{"id":"R2008","pred":"nsubj","subj":"T3914","obj":"T3919"},{"id":"R2012","pred":"punct","subj":"T3915","obj":"T3916"},{"id":"R2015","pred":"appos","subj":"T3916","obj":"T3914"},{"id":"R2019","pred":"punct","subj":"T3917","obj":"T3918"},{"id":"R2023","pred":"nsubj","subj":"T3918","obj":"T3919"},{"id":"R2026","pred":"conj","subj":"T3919","obj":"T3911"},{"id":"R2033","pred":"mark","subj":"T3920","obj":"T3928"},{"id":"R2037","pred":"det","subj":"T3921","obj":"T3922"},{"id":"R2041","pred":"nsubj","subj":"T3922","obj":"T3928"},{"id":"R2045","pred":"prep","subj":"T3923","obj":"T3922"},{"id":"R2048","pred":"amod","subj":"T3924","obj":"T3926"},{"id":"R2052","pred":"amod","subj":"T3925","obj":"T3926"},{"id":"R2056","pred":"pobj","subj":"T3926","obj":"T3923"},{"id":"R2060","pred":"aux","subj":"T3927","obj":"T3928"},{"id":"R2064","pred":"ccomp","subj":"T3928","obj":"T3919"},{"id":"R2068","pred":"det","subj":"T3929","obj":"T3931"},{"id":"R2071","pred":"amod","subj":"T3930","obj":"T3931"},{"id":"R2075","pred":"attr","subj":"T3931","obj":"T3928"},{"id":"R2079","pred":"prep","subj":"T3932","obj":"T3931"},{"id":"R2081","pred":"det","subj":"T3933","obj":"T3934"},{"id":"R2084","pred":"pobj","subj":"T3934","obj":"T3932"},{"id":"R2087","pred":"prep","subj":"T3935","obj":"T3934"},{"id":"R2091","pred":"amod","subj":"T3936","obj":"T3938"},{"id":"R2095","pred":"amod","subj":"T3937","obj":"T3938"},{"id":"R2097","pred":"pobj","subj":"T3938","obj":"T3935"},{"id":"R2100","pred":"amod","subj":"T3939","obj":"T3941"},{"id":"R2104","pred":"nummod","subj":"T3940","obj":"T3941"},{"id":"R2107","pred":"conj","subj":"T3941","obj":"T3931"},{"id":"R2111","pred":"punct","subj":"T3942","obj":"T3919"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
bionlp-st-ge-2016-test-tees
{"project":"bionlp-st-ge-2016-test-tees","denotations":[{"id":"T3604","span":{"begin":46,"end":56},"obj":"Negative_regulation"},{"id":"T3603","span":{"begin":46,"end":56},"obj":"Negative_regulation"},{"id":"T3602","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T3601","span":{"begin":60,"end":89},"obj":"Protein"}],"relations":[{"id":"R1751","pred":"themeOf","subj":"T3601","obj":"T3603"},{"id":"R1753","pred":"themeOf","subj":"T3602","obj":"T3604"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}
testone
{"project":"testone","denotations":[{"id":"T2108","span":{"begin":95,"end":113},"obj":"Protein"},{"id":"T2107","span":{"begin":60,"end":89},"obj":"Protein"}],"text":"The favorable clinical benefits obtained with inhibitors of tumor necrosis factor (TNF)-α) and interleukin (IL)-1 suggest that the blockade of key inflammatory cytokines has been the important issue in the development of new therapeutic applications [2]."}